Company intelligence / Profile preview

Protein Sciences

Meriden, Connecticut, United Stateslabs.iqvia.com ↗

Ownership: Private
Employees: ~48
Development stage: Commercial

Overview

The company developed Flublok®, the first FDA-approved recombinant influenza vaccine, showing a clinically significant efficacy advantage over traditional egg-based vaccines in adults ≥50 years old. Sanofi acquired the company in August 2017 for $750M to expand its non-egg-based flu vaccine portfolio.

Therapeutic areas: Infectious Diseases
Modalities: Recombinant protein vaccines
Industry: Biotech

Drug pipeline

1 asset

Flublok

Commercial

Indications: pandemic influenza A (H1N1-2009)

Partnerships

U.S. Biomedical Advanced Research and Development Authority (BARDA)Sinergium Biotecnologia SAOrygen Biotecnologia

Beyond the preview

Go deeper on Protein Sciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Protein Sciences.

Explore the full profile